BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3(R) Test in Heart Failure

BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM
Galectin-3(R) Test in Heart Failure

European Society of Cardiology Heart Failure Congress Features 15
Presentations and Two Symposia on Galectin-3

WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) today announced the presentation of new clinical research data
on the BGM Galectin-3® test in heart disease at the 2013 European Society of
Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal.Among the
highlights was a late-breaking oral presentation of results from the Aldo-DHF
Biomarker Substudy which demonstrated the usefulness of galectin-3 testing for
assessing functional capacity and clinical prognosis in patients diagnosed
with a form of heart failure known as Heart Failure with Preserved Ejection
Fraction (HFpEF).^i Heart Failure with Preserved Ejection Fraction is the
fastest growing type of clinical heart failure in the United States and
Europe, disproportionately affecting women and accounting for one-third to
one-half of all hospital admissions for heart failure.^ii

The Aldo-DHF study findings were presented by Dr. Frank Edelmann of the
Department of Cardiology and Pneumology and the German Center for
Cardiovascular Research at the University of Göttingen. The title of Dr.
Edelmann's late-breaking special sessions oral presentation was Galectin-3
Reflects Functional Capacity and Clinical Outcome in Heart Failure with
Preserved Ejection Fraction (The Aldo-DHF Biomarker Substudy.)

"Galectin-3 has the potential to be a valuable test in clinical risk
stratification for heart failure patients. In this study of 422 patients with
diagnosed HFpEF, elevated galectin-3 levels, and particularly changes in
galectin-3 over time, were statistically predictive of subsequent
hospitalizations and mortality," commented Dr.Edelmann.

"The data presented at ESC-HF further demonstrate that galectin-3 may be an
important determinant of heart failure risk across the clinical spectrum of
disease," stated Paul Sohmer, President and CEO of BG Medicine."Unplanned
hospitalizations of patients with heart failure are a major cost burden on
healthcare systems, particularly among patients with a diagnosis of HFpEF, one
of the fastest growing but most difficult types of heart failure to identify
and treat.The data presented at ESC-HF suggest that galectin-3 testing may
help to identify HFpEF patients who are at risk of near-term adverse events."

In addition to the presentation of the Aldo-DHF Biomarker Substudy, other
research on galectin-3 in heart disease presented at the ESC-HF meeting
included:

-Reduction in 30 Day Death and Heart Failure Rehospitalization with
Mineralocorticoid Receptor Antagonists: An Analysis from the COACH Study, A.
Maisel (San Diego, US), et. al.

  - Late-breaking Research Abstract Presentation

-Galectin-3 in Heart Failure with Preserved Versus Reduced Ejection Fraction,
R. Santhanakrishnan (Singapore), et al.

  - Abstract P-1737

-Elevated Plasma Galectin-3 Levels Correlate with Echocardiographic
Parameters of Diastolic Dysfunction in Patients with Stable Heart Failure with
Preserved Ejection Fraction (HFpEF), B. Munoz Calvo (Alcalá de Henares,
Spain), et al.

  - Abstract P-1301

-Galectin-3, Soluble ST-2 Protein and Echocardiographic Parameters in
Clinically Stable Dilated Cardiomyopathy Patients, C.A. Wojciechowska (Zabrze,
Poland), et al.

  - Abstract P-595

In addition to the presentations of original research, two conference
satellite symposia were also held at ESC-HF: "Biomarker-guided Therapy in
Heart Failure– Role of Galectin-3", and "Reducing Hospital Readmissions for
Heart Failure– Can Galectin-3 Help?"

About BGM Galectin-3 Testing

Galectin-3 has been implicated in a variety of biological processes important
in the development and progression of heart failure. Higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care. Galectin-3 testing may be useful in helping
physicians determine which patients are at higher risk of death or
hospitalization, including 30-day readmission.www.galectin-3.com

AboutBG Medicine, Inc.

BG Medicine, Inc.(Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. For additional information aboutBG Medicine, heart failure
and galectin-3 testing, please
visitwww.bg-medicine.comandwww.galectin-3.com.

The BG Medicine Inc. logo is available for download here

Forward Looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our belief in the usefulness of galectin-3 testing for
assessing functional capacity and clinical prognosis in patients diagnosed
with HFpEF; our belief that HFpEF is the fast growing type of clinical heart
failure in the United States and Europe and one of the most difficult types of
heart failure to identify and treat; our belief in the usefulness of
galectin-3 testing in helping physicians identify which patients are at higher
risk of death, hospitalization or readmission; our belief in the ability of
elevated galectin-3levels and changes in galectin-3 over time to predict
subsequent hospitalization and mortality; our belief that galectin-3 testing
can help clinicians customize treatment to improve patient management for
HFpEF patients; our belief that identification of high-risk patients using
galectin-3 testing may become an important part of patient care; our belief
that unplanned hospitalizations of patients with heart failure are a major
cost burden on healthcare systems, particularly among HFpEF patients; and our
belief in the importance of repeated testing of galectin-3 for monitoring
disease progression and risk stratification. Forward-looking statements are
based on management's current expectations and involve inherent risks and
uncertainties which could cause actual results to differ materially from those
in the forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our recent filings with the Securities and Exchange
Commission, including our most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. We urge you to consider those risks and uncertainties in
evaluating our forward-looking statements. We caution readers not to place
undue reliance upon any such forward-looking statements, which speak only as
of the date made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any updates or
revisions to any forward-looking statement contained herein (or elsewhere) to
reflect any change in our expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based.

^i Fonarow GC, Stough WG, et al. Characteristics, treatments, and outcomes of
patients with preserved systolic function hospitalized for heart failure: a
report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007 Aug
21;50(8):768-77.

^ii Gurwitz JH, Magid DJ, et al. Contemporary prevalence and correlates of
incident heart failure with preserved ejection fraction. Am J Med. 2013
May;126(5):393-400.

CONTACT: Media Contact:
         Douglas MacDougall, MacDougall Biomedical Communications
         (781) 235-3060
        
         Investor Contact:
         Chuck Abdalian, EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.